Recent use of nonsteroidal anti-inflammatory agents (NSAIDs) do not protect against development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), a new study concluded.
Accumulating evidence suggests that inflammation may contribute to the development of BPH and LUTS, according to the investigators who conducted the study. Therefore, they noted, it is plausible that anti-inflammatory agents, such as aspirin and other NSAIDs, may reduce the risk of BPH/LUTS. Their study, however, showed that NSAIDS do not lower that risk, according to a report published online ahead of print in BJU International.
The researchers, led by Siobhan Sutcliffe, MD, of Washington University School of Medicine in St. Louis, studied 4,771 men who participated in the Prostate, Lung, Colorectal and Ovarian Cancer Screen trial and did not have BPH/LUTS at study entry. Dr. Sutcliffe’s team analyzed information related to regular aspirin or ibuprofen use in relation to the incidence of six BPH/LUTS definitions: diagnosis of an enlarged prostate/BPH, nocturia (waking two or more times per night to urinate), finasteride use, any self-reported BPH/LUTS, prostate enlargement (estimated prostate volume of 30 mL or greater on any follow-up digital rectal examination) and a greater than 1.4 ng/mL elevation in PSA level on any follow-up PSA test. The researchers found no association between regular aspirin or ibuprofen use and development of BPH/LUTS.